OBINUTUZUMAB VS. IBRUTINIB IN THE TREATMENT OF TREATMENT-NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA -A COST-COMPARISON STUDY IN COLOMBIA

被引：0
|
作者：
Vecino-Ortiz, A. [1 ]
Diaz-Sotelo, O. D. [2 ]
Rodriguez, M. [3 ]
Diaz-Toro, Y. R. [4 ]
Moreno-Silva, N. A. [4 ]
机构：
[1] Univ Los Andes, Bogota, Colombia
[2] Random Fdn, Bogota, Colombia
[3] Fdn Santa Fe Bogota, Bogota, Colombia
[4] Prod Roche SA, Bogota, Colombia
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2577
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN25
引用
收藏
页码：A875 / A875
页数：1
相关论文
共 50 条
  • [1] Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Abruzzo, Lynne V.
    Andersen, Barbara L.
    Awan, Farrukh T.
    Bhat, Seema A.
    Dean, Allison
    Lucas, Margaret
    Banks, Christin
    Grantier, Cara
    Heerema, Nyla A.
    Lozanski, Gerard
    Maddocks, Kami J.
    Valentine, Thomas R.
    Weiss, David M.
    Jones, Jeffrey A.
    Woyach, Jennifer A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3626 - +
  • [2] Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Awan, Farrukh T.
    Hoffman, Corrinne
    Maddocks, Kami J.
    Reid, Mark
    Woyach, Jennifer A.
    Whitlow, Thomas
    Jones, Jeffrey A.
    Byrd, John C.
    BLOOD, 2018, 132
  • [3] Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Emeribe, Ugochinyere
    Gaitonde, Priyanka
    Cai, Ling
    BLOOD, 2021, 138
  • [4] Phase I study of ibrutinib in Japanese patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shibayama, Hirohiko
    Teshima, Takanori
    Choi, Ilseung
    Hatake, Kiyohiko
    Sekiguchi, Naohiro
    Yoshinari, Nozomi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (04) : 179 - 186
  • [5] Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Gulrajani, Michael
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng
    Wang, Min-Hui
    Byrd, John C.
    CANCER DISCOVERY, 2020, 10 (03) : 394 - 405
  • [6] ELEVATE TN: Phase 3 Study of Acalabrutinib Combined With Obinutuzumab or Alone vs Obinutuzumab Plus Chlorambucil in Patients With Treatment-Naive Chronic Lymphocytic Leukemia
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 2 - 4
  • [7] Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naive Patients With Chronic Lymphocytic Leukemia: A Cross-Trial Comparison
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 2 - 3
  • [8] Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
    Cerquozzi, Sonia
    Owen, Carolyn
    BIOLOGICS-TARGETS & THERAPY, 2015, 9 : 13 - 22
  • [9] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Grever, Michael R.
    Kittai, Adam S.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Patel, Priti
    Munugalavadla, Veerendra
    Butturini, Anna
    Xu, Yan
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2020, 136
  • [10] Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
12345